About Enliven Therapeutics
Enliven Therapeutics is a company based in Boulder (United States) founded in 2019 by Anish Patel, Sam Kintz, and Joe Lyssikatos.. The company has 62 employees as of December 31, 2024. Enliven Therapeutics offers products and services including BCR-ABL Program, HER2 Program, and Additional Programs. Enliven Therapeutics operates in a competitive market with competitors including Nuvalent, Nura Bio, Abbisko Therapeutics, NewAmsterdam Pharma and Skyhawk Therapeutics, among others.
- Headquarter Boulder, United States
- Employees 62 as on 31 Dec, 2024
- Founders Anish Patel, Sam Kintz, Joe Lyssikatos
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Enliven Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-89.02 M-24.36as on Dec 31, 2024
-
EBITDA
$-104.24 M-25.24as on Dec 31, 2024
-
Latest Funding Round
$90 M (USD), Post-IPO
Mar 21, 2024
-
Investors
Fidelity Investments
& 12 more
-
Employee Count
62
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Enliven Therapeutics
Enliven Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ELVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Enliven Therapeutics
Enliven Therapeutics offers a comprehensive portfolio of products and services, including BCR-ABL Program, HER2 Program, and Additional Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops inhibitors for BCR-ABL mutations in cancer treatment.
Targets HER2 for improved cancer therapy outcomes.
Focuses on various kinase inhibitors for oncology applications.
Unlock access to complete
Unlock access to complete
Funding Insights of Enliven Therapeutics
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $90.0M
- First Round First Round
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Post-IPO - Enliven Therapeutics | Valuation |
investors |
|
| Feb, 2023 | Amount | Post-IPO - Enliven Therapeutics | Valuation |
investors |
|
| Dec, 2020 | Amount | Post-IPO - Enliven Therapeutics | Valuation | Cormorant Asset Management , Surveyor Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Enliven Therapeutics
Enliven Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Roche and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC & PE firm focused on healthcare sector
|
Founded Year | Domain | Location | |
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Healthcare startups are funded by this venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Enliven Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Enliven Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Enliven Therapeutics Comparisons
Competitors of Enliven Therapeutics
Enliven Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuvalent, Nura Bio, Abbisko Therapeutics, NewAmsterdam Pharma and Skyhawk Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| domain | founded_year | HQ Location |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| domain | founded_year | HQ Location |
Developing novel small molecule drugs for immunomodulatory pathways to treat cancer
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cardio-metabolic diseases are developed using obicetrapib.
|
|
| domain | founded_year | HQ Location |
RNA-modifying drug candidates are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Enliven Therapeutics
Frequently Asked Questions about Enliven Therapeutics
When was Enliven Therapeutics founded?
Enliven Therapeutics was founded in 2019.
Where is Enliven Therapeutics located?
Enliven Therapeutics is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Who is the current CEO of Enliven Therapeutics?
Sam Kintz is the current CEO of Enliven Therapeutics. They have also founded this company.
How many employees does Enliven Therapeutics have?
As of Dec 31, 2024, the latest employee count at Enliven Therapeutics is 62.
What does Enliven Therapeutics do?
Enliven Therapeutics was founded in 2019 and is based in Boulder, United States. Precision oncology therapeutics are developed by the company for solid tumors and blood cancers. The pipeline includes ELVN-001, a small molecule kinase inhibitor that targets the BCR-ABL gene fusion in blood cancers, and ELVN-002, a HER2 inhibitor designed for activity against various HER2 mutations in non-small cell lung cancer and other solid tumors.
Who are the top competitors of Enliven Therapeutics?
Enliven Therapeutics's top competitors include Nuvalent, Abbisko Therapeutics and Nura Bio.
What products or services does Enliven Therapeutics offer?
Enliven Therapeutics offers BCR-ABL Program, HER2 Program, and Additional Programs.
Is Enliven Therapeutics publicly traded?
Yes, Enliven Therapeutics is publicly traded on NASDAQ under the ticker symbol ELVN.
Who are Enliven Therapeutics's investors?
Enliven Therapeutics has 13 investors. Key investors include Fidelity Investments, Roche, Orbimed, Janus Henderson Investors, and RA Capital.
What is Enliven Therapeutics's ticker symbol?
The ticker symbol of Enliven Therapeutics is ELVN on NASDAQ.